Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

Inclusion Criteria: * Men and women \>/= 65 years * Ambulatory, * Community dwelling, * Slow gait speed (\<1 m/second), * Mild Cognitive Impairment (Telephone MoCA score \<21, which is indicative of cognitive impairment) Exclusion Criteria, or as per clinical judgment: * Telephone MoCA score \<10 points * Unwilling to take study medications or follow study protocol * Inability to independently perform Katz Activities of Daily Living (ADLs), * Allergies to Dasatinib or Quercetin, * Hospitalization within 6 months, * Unstable coronary artery disease (myocardial infarction within 6 months or angina), * Stroke or transient ischemic attack in the past 6 months, * Chronic heart failure, * Current or chronic history of liver disease, * Neurodegenerative disease including Parkinson's disease, * Anemia, * Chronic renal disease, * Drug or alcohol abuse in the last 5 years, * QTc prolongation, * Thrombocytopenia, * Neutropenia, * Prolonged prothrombin time or INR, * Indications of current fluid retention, * History or current diagnosis of pulmonary hypertension, * Inability to insonate the middle cerebral artery through a temporal bone window on at least one side using transcranial Doppler ultrasound, or * Chronic use of any of the following medications: anti-arrhythmic medications, antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as Quercetin or Dasatinib.